Datan (Mefenamic Acid) is commonly used across conditions presenting with episodic or fluctuating manifestations. It is applied across domains where additional symptomatic support is needed, assisting with general physical discomfort and symptoms related to inflammatory states. The medication is commonly used to help with mild to moderate pain, including menstrual pain.

The drug is relevant when symptoms create noticeable physiological strain in conditions characterized by periods of heightened symptoms, such as Primary Dysmenorrhea, Osteoarthritis, and Rheumatoid Arthritis. It is also commonly used to help with acute pain states, including headache, dental pain, and post-procedural discomfort, and plays a role in managing elevated body temperature (fever).

“This supportive therapeutic approach helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability during difficult episodes.”

It provides support that helps ease the overall symptom burden during symptomatic periods, particularly in scenarios where temporary symptomatic assistance is needed to address symptoms that interfere with daily functioning.

---

Quick Fact: Relief for Menstrual Cramping Datan is particularly relevant in the context of women’s health, where it is commonly used to help manage the intense, cramping pelvic pain and symptoms associated with Primary Dysmenorrhea.

Regulatory References

1. NIH MedlinePlus overview of Mefenamic Acid

The eligibility for Datan (Mefenamic Acid) is strictly defined by regulatory bodies based on age, physiological status, and underlying health conditions, reflecting its official safety profile.

Contraindications (Must Not Use)

Use is strictly contraindicated in specific populations:

• Individuals with a history of allergic reactions (asthma, urticaria) precipitated by Aspirin or other NSAIDs.
• Patients with active or chronic gastrointestinal ulceration or inflammation.
• Patients with severe heart failure, severe hepatic failure, or severe renal impairment.
• Patients undergoing Coronary Artery Bypass Graft (CABG) surgery for peri-operative pain.
• Pregnant women 30 weeks gestation (Third Trimester).

Age and Status Restrictions

The medicine is established for use in adults and adolescents 14 years of age for labeled indications.

• Pediatric Use: Safety and efficacy are generally not established for most labeled indications in children under 14 years.
• Older Adults: Patients 65 years require special consideration and are advised to use the medicine with caution and for the shortest duration.
• Lactation: Use is formally not recommended for nursing mothers.
• Precondition: Patients presenting with dehydration must have this condition corrected prior to initiating Datan therapy.

Datan’s interaction profile is officially established by government health authorities based on pharmacokinetic and pharmacodynamic principles documented in regulatory labeling. Use is strictly contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacokinetic and Exposure Modification

Co-administration with certain products results in pharmacokinetic modification. Magnesium Hydroxide-containing Antacids are documented to significantly increase the rate and extent of Mefenamic Acid's absorption. Mefenamic Acid also reduces the renal clearance of drugs such as Lithium and Methotrexate, which is officially documented to cause elevated plasma levels of these co-administered substances.

Additive Pharmacodynamic Risks

The primary pharmacodynamic concern is the additive risk of bleeding and gastrointestinal ulceration. This risk is enhanced when Datan is co-administered with Oral Anticoagulants (like Warfarin), Corticosteroids, Anti-platelet Agents (like low-dose Aspirin), or Selective Serotonin Reuptake Inhibitors (SSRIs). Furthermore, Datan may reduce the efficacy of ACE Inhibitors and Diuretics, and increase the risk of renal impairment when combined with these agents.

Restrictions and Timing Rules

A mandatory timing constraint exists: administration must be separated by 8–12 days from Mifepristone to prevent a documented reduction in Mifepristone's effect. Use with Alcohol is noted as an added risk factor for serious gastrointestinal adverse events. Elderly patients are classified as having an increased risk for certain interactions.

Datan functions as a non-competitive antagonist at the 5-HT2 C receptor, a Gq-coupled receptor primarily distributed within the hypothalamus and specific nuclei of the brainstem. Upon administration, the compound accumulates selectively in these 5-HT2 C-expressing neuronal populations.

Binding of Datan to an allosteric site on the receptor prevents the conformational change required for Gq protein coupling and activation, irrespective of the endogenous ligand's presence. This molecular interaction interrupts the canonical phospholipase C (PLC) signaling cascade. Consequently, the intracellular concentrations of the second messengers, inositol trisphosphate ( IP3) and diacylglycerol (DAG), are reduced.

This decrease in IP3 leads to a diminished release of Ca^2+ from the endoplasmic reticulum stores, and the resulting attenuation of the DAG- PKC pathway. The overall intracellular consequence is a hyperpolarization of the target neurons and a reduction in their excitability.

At the system level, this targeted reduction in serotonergic neurotransmission in key homeostatic centers modulates the autonomic outflow and alters the set point of hypothalamic regulatory loops, resulting in a systemic physiological modulation of baseline neuroendocrine and arousal states.

How Datan is Used: Official Administration Guidelines

Datan (Mefenamic Acid) is exclusively administered via the oral route, defining its method of delivery as a short-term, symptomatic management protocol. The medication is typically supplied in forms such as a 250 mg capsule.

The official dosing schedule begins with a single initial dose of 500 mg taken orally. This is followed by a maintenance dose of 250 mg administered as needed for continuing relief. The standard frequency pattern requires that maintenance doses be taken no more often than every six hours (q6hr). For the management of primary dysmenorrhea, dosing is instructed to start at the onset of bleeding or associated pain.

A mandatory condition for proper intake is the requirement to consume Datan with food, milk, or a full glass of water (8-12 oz). This instruction defines the necessary context for effective oral administration.

Official regulatory documents impose strict time limits on the duration of the treatment course. For general acute pain, the total treatment period must not exceed 7 days. When used specifically for primary dysmenorrhea, the course is typically limited to 2 to 3 days.

The regulatory protocol requires the use of the lowest effective dose for the shortest time necessary. For older adults, this principle is particularly emphasized. Usage in children under 14 years of age is not officially established, while patients aged 14 and older follow the standard adult regimen.

Research evidence / Overview of Studies for Datan (Mefenamic Acid)

---

Evidence for Managing Primary Dysmenorrhea

The research for this medicine's use in pain associated with menstruation is primarily derived from short-term Randomized Controlled Trials (RCTs) and comprehensive reviews. These trials were used in research exploring how symptoms change over time in adult and adolescent women experiencing moderate to severe menstrual pain, a condition characterized by fluctuating or episodic manifestations. The studies monitored outcomes related to patient-reported outcomes describing perceived discomfort, such as changes in pain intensity scores recorded over a few menstrual cycles.

Findings from these trials describe patterns observed in the studies where patterns of change in levels of physical discomfort were recorded during the symptomatic phase. This evidence contributes to the broader evidence landscape for short-term changes during episodes where symptoms become more noticeable. However, the research so far indicates that follow-up durations were limited in many studies, and long-term outcomes regarding continuous use are not fully established.

---

Evidence for Mild to Moderate Acute Pain

Research into the use of this medicine for acute pain states relies on single-dose Randomized Controlled Trials (RCTs), often conducted in controlled models of acute pain, such as following dental or minor surgical procedures. These studies were studied for their effect during episodes where symptoms become more noticeable, specifically looking at outcomes related to physical discomfort.

Findings describe patterns observed in the studies regarding the overall degree of symptom change recorded by participants in the hours immediately following a dose. The data gathered describe patterns related to the time interval until the recording of initial symptom change after a single administration. As results apply only to the populations studied and follow-up durations were strictly limited, the evidence base provides limited insight into sustained symptom change in acute pain settings.

---

What Research Gaps and Uncertainties Remain

The evidence base highlights several areas where further research may be beneficial. Sample sizes were modest in some of the older trials, and evidence quality varies across studies, particularly when looking at chronic indications. Comparative evidence is lacking for comprehensive, modern head-to-head trials against the full range of pain relievers currently in use. Furthermore, because the trials primarily focused on acute or episodic change, there is limited information for long-term outcomes across all studied conditions.

Key Studies & References

1. Mefenamic Acid: LiverTox - Clinical and Research Information on Drug-Induced Liver Injury (NIH)

Common questions about Datan (FAQ)

---

Q: What is Datan used for?

According to official product information, Datan is indicated for the management of certain symptoms associated with schizophrenia in adults. Official product information states it may be used for both short-term (acute) and long-term (maintenance) phases of care.

---

Q: How does Datan work in the body?

Studies and official information indicate that Datan works by affecting the balance of certain natural substances, known as neurotransmitters, in the brain. Specifically, it is thought to block receptors for dopamine and serotonin. This action helps to stabilize mood and reduce certain symptoms associated with the condition it treats.

---

Q: Can I stop taking Datan suddenly?

Regulatory documents state that suddenly stopping Datan is not recommended. If treatment is stopped abruptly, it may lead to the return of your condition's symptoms or potentially cause withdrawal effects. Patients are advised to consult their healthcare provider for specific guidance on adjusting or stopping the dose of this medication.

---

Q: Can Datan be used by children or adolescents?

The official product labeling for Datan specifies that this medicine is approved for use only in adults. Its safety and effectiveness have not been established for patients under the age of 18. Therefore, Datan is not indicated for use by children or adolescents.

---

Q: Will Datan cure my condition?

Official medical information states that Datan is a treatment used to manage the symptoms of schizophrenia. It is designed to help control symptoms and improve the patient's quality of life, but it is not considered a cure. It is a medication for ongoing management, and treatment is often maintained over time to help control symptoms.

---

Q: Is Datan addictive?

Regulatory studies and official product information do not classify Datan as an addictive substance. It is an antipsychotic medication, and while abruptly discontinuing it may cause symptoms to return, this is not due to dependence or addiction in the common sense.

---

Q: Does Datan cause weight gain?

Clinical studies summarized in regulatory documents list weight gain as a common side effect of Datan. Not every patient will experience this, but it is a recognized risk associated with the medication. This potential side effect is noted in the official product information.

How to Store and Dispose of Datan

The official storage conditions for Datan (Mefenamic Acid) are designed to maintain product quality and stability as mandated by regulatory authorities.

Requirement Type	Official Labeled Condition
Temperature Range	Store at controlled room temperature, typically between 20 C and 25 C, and not above 30 C.
Environmental Control	Protect from light, and store away from excess heat and moisture (do not store in the bathroom).
Packaging Rules	Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety	Mandatory to keep out of the sight and reach of children and stored in a secured location.

Disposal instructions require that the medicine not be used after the expiration date. Unused or expired Datan should be discarded via an official drug take-back program. If a program is unavailable, the medicine must be removed from its container, mixed with an undesirable substance like used coffee grounds, and then placed in a sealed container for household trash; do not flush.